Several studies have reported the association between a variety of malignancies and HLA genes. Conflicting data have been reported on HLA association and melanoma, and particularly for DQB1*0301 that has been found associated with the progression of the disease in a study on Caucasians (Lee JF, Int J Cancer1994; 59: 510), whereas no correlation has been found in Italian patients (Lombardi ML, J Immunother; 1998; 21:435). We here report serological and molecular analysis, by PCR-SSP, of HLA class I and II loci in 266 melanoma patients and 300 ethnically matched controls with the aim to correlate HLA alleles frequency with course and spreading of the disease. Results showed an increase of Al (28% vs19%; p=0.008) and a decrease of B13 (8.5% vs 14,1%; p=0.03), among HLA class I antigens and an increase of DRB1*01,DQB 1*0501 (9.9% vs 5.4%; p=0.021) and a decrease of DRB1*04, DQB 1*0302 (5.4% vs 8.9%; p=0.045) among HLA class II alleles. HLA alleles frequency has been also evaluated respect to progression of the disease, sub-grouping patients with localized (I and II Stage) or metastatic (III and IV Stage) melanoma according the AJCC classification at presentation. HLA A1, DRB1*01 and DRB1*04 seem to be associated with disease incidence since they have been found increased in both localized and metastatic stages of the disease. On the contrary, B13 and B44 seem to be correlated with progression since both have been found decreased only in metastatic stages. Since HLA antigens are the restricting elements presenting several melanoma associated antigens-derived peptides to cytotoxic T-lymphocytes, HLA typing of patient populations can help to better address selected vaccine therapies.
|Number of pages||1|
|Journal||European Journal of Immunogenetics|
|Publication status||Published - 2001|
ASJC Scopus subject areas